P-047 - WITHDRAWN - MODEL INFORMED DEVELOPMENT OF LRRK2 INHIBITOR DNL201 IN PARKINSON’S DISEASE: A POPPK-PD APPROACH FOR DOSE SELECTION WITH A SUSTAINED RELEASE (SR) FORMULATION.
C. Ng, S. Huntwork-Rodriguez, M. Borin, B. Wong, E. Negrou, A. Kay, M. Troyer, D. Jennings, V. Daryani; Denali Therapeutics Inc., South San Francisco, CA, USA.
.png)